Notice 20 May 2025 ofac, financial transactions, international business, sanctions, treasury, compliance

🚫OFAC Sanctions Action

The U.S. Department of the Treasury's Office of Foreign Assets Control (OFAC) is publishing the names of one or more persons that have been placed on OFAC's Specially Designated Nationals and Blocked Persons List (SDN List) based on OFAC's determination that one or more applicable legal criteria were satisfied. All property and interests in property subject to U.S. jurisdiction of these persons are blocked, and U.S. persons are generally prohibited from engaging in transactions with them.

Learn More
Notice 20 May 2025 labor, training, safety, mining, compliance, business, regulation

⚒️DOL Notice

The Department of Labor (DOL) is submitting this Mine Safety and Health Administration (MSHA)-sponsored information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). Public comments on the ICR are invited.

Learn More
Notice 20 May 2025 fluorouracil, chemotherapy, regulatory compliance, healthcare, dihydropyrimidine dehydrogenase, fda

💉FDA Notice on DPD Deficiency and Fluoropyrimidine Drugs

The Food and Drug Administration (FDA or Agency) is announcing the establishment of a docket to solicit public comment for information on dihydropyrimidine dehydrogenase (DPD) deficiency and the use of fluorouracil and capecitabine (both fluoropyrimidine chemotherapy drugs). The purposes of the docket establishment are to foster Agency transparency and to solicit input on the currently available information on DPD deficiency and the use of fluorouracil and capecitabine.

Learn More
Notice 19 May 2025 meeting, hhs, advisory council, regulatory, nih, health, bethesda

🏥Notice of Meeting Update for National Heart, Lung, and Blood Advisory Council

This notice announces a change in the format and location of the National Heart, Lung, and Blood Advisory Council meeting. Originally scheduled as a virtual meeting, it will now take place in person at the Porter Neuroscience Research Center in Bethesda, Maryland, and will be partially closed to the public.

Learn More
Notice 19 May 2025 energy, oglethorpe power corporation, compliance, environmental analysis, federal energy regulatory commission, regulation

⚡Revised Procedural Schedule for Oglethorpe Power Project

The Federal Energy Regulatory Commission announces a revised procedural schedule for the re-licensing of the 904-megawatt Rocky Mountain Pumped Storage Project No. 2725 by Oglethorpe Power Corporation. The schedule details deadlines for scoping documents and environmental analysis, ensuring stakeholder engagement throughout the process.

Learn More
Notice 19 May 2025 regulatory compliance, energy, environmental assessment, project relicensing, hydropower

⚡Spencer Mountain Hydropower Relicensing

The Department of Energy announces the revised procedural schedule for the environmental assessment concerning the relicensing of Spencer Mountain Hydropower, LLC’s 0.64-megawatt project. This includes anticipated key milestones, particularly the issuance of the environmental assessment, essential for evaluating the project's impact and ensuring compliance with regulatory standards.

Learn More
Notice 19 May 2025 regulatory compliance, public meeting, fda, user fees, prescription drug user fee act, pharmaceutical

💊FDA Meeting on Reauthorization of Prescription Drug User Fee Act

The Food and Drug Administration (FDA, the Agency, or we) is hosting a public meeting to discuss proposed recommendations for the reauthorization of the Prescription Drug User Fee Act (PDUFA) for fiscal years (FYs) 2028 through 2032. PDUFA authorizes FDA to collect user fees to support the process for the review of human drug applications. The current legislative authority for PDUFA expires in September 2027. At that time, new legislation will be required for FDA to continue collecting prescription drug user fees in future fiscal years. The Federal Food, Drug, and Cosmetic Act (FD&C Act) directs that FDA begin the PDUFA reauthorization process by publishing a notice in the Federal Register requesting public input and holding a public meeting where the public may present its views on the reauthorization. FDA invites public comment as the Agency begins the process to reauthorize the program in FYs 2028 through 2032. These comments will be published and available on FDA's website.

Learn More
Notice 19 May 2025 fpga technology, nasdaq, market data, gemx, regulatory change

📈Nasdaq GEMX Proposes FPGA Technology for Market Data Feeds

The SEC publishes a notice regarding Nasdaq GEMX's proposed rule change to offer FPGA technology as an optional delivery mechanism for its Depth of Market Data Feed. This initiative is aimed at improving data transmission predictability and reducing jitter, catering to the evolving demands of market participants. Submissions for comments are invited in response to this proposal.

Learn More
Notice 19 May 2025 hydroelectric, energy, compliance, water quality, regulation, new hampshire

💧Notice of Water Quality Certification for Ampersand Gilman Hydro

The Federal Energy Regulatory Commission has issued notice concerning a Clean Water Act certification request for the Ampersand Gilman Hydro project. New Hampshire Department of Environmental Services is given a deadline to act on the request, which, if unmet, could lead to project delays or regulatory challenges.

Learn More
Notice 19 May 2025 securities, enforcement, washington dc, legal, compliance, sec, regulation, meetings

🔒SEC Closed Meeting Notice - Sunshine Act Compliance 2025

The SEC issued a notice regarding a closed meeting under the Sunshine Act, set to discuss various legal matters including injunctions, administrative proceedings, and enforcement actions. The meeting is not open to the public, indicating the sensitivity of the topics at hand, which may include significant developments affecting business regulations and compliance.

Learn More